Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 48,493 shares, a growth of 52.6% from the July 15th total of 31,784 shares. Based on an average daily volume of 11,695 shares, the days-to-cover ratio is presently 4.1 days.
Relief Therapeutics Stock Performance
Shares of OTCMKTS RLFTF opened at $0.27 on Thursday. The company’s 50 day moving average price is $0.27 and its 200-day moving average price is $0.55. Relief Therapeutics has a 52-week low of $0.16 and a 52-week high of $4.88.
Relief Therapeutics Company Profile
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
Featured Stories
- Five stocks we like better than Relief Therapeutics
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
